InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.91
(
0.53%
)
Bitcoin
59,791.91
(
-3.60%
)
Post# of 252474
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: pharmaclown35 post# 82895

Wednesday, 08/26/2009 2:07:44 PM

Wednesday, August 26, 2009 2:07:44 PM

Post# of 252474
Assuming only 30% of patients respond to Fampridine, and only half (I'm underestimating) of all MS patients in the US (400–450K) have some degree of walking disability, then about 60K patients would be candidates for treatment with the drug. Agree that use will be limited to patients with significant degree of disability in case the drug will get heavily blackboxed (risk of seizure).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up